Seasonal Allergic Rhinitis
Conditions
Keywords
Phase 2, SAR, STAHIST
Brief summary
To report and compare total symptom scores, nasal symptom scores, post-nasal drip symptom scores, and adverse reactions in and between SAR subjects on active drug and SAR subjects on placebo.
Detailed description
This double-blind, placebo-controlled study will evaluate the efficacy and safety of STAHIST vs. placebo over a 2-week period in 100 study subjects with a history of SAR for at least two years. The study will take place in two sites, Louisville, KY and South Bend, IN. SAR symptoms to be scored and compared include: nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip.
Interventions
DRUGPlacebo
Tablet, one BID
DRUGSTAHIST
STAHIST in tablet form dosed one BID
Sponsors
Magna Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Males and females of any ethnic group between 18 and 60 years of age. 2. History of moderate to severe SAR for at least two years. 3. Subjects' symptoms resulting from the irritation of sinus, nasal and upper respiratory tract tissues will include the five symptoms that are th focus of this study: nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip. Subjects must have a TSS baseline score of at least 8 on the S5 Subject Diary. 4. Prior to study drug administration, subjects' good health will be confirmed by medical history and physical examination, including pregnancy test (urine dip) before study inception. 5. Allergic hypersensitivity will be confirmed by the physician or well established patient medical history. 6. Subject's compliance with requisite run-in period for each subject will be confirmed by investigator/designee.
Exclusion criteria
1. Pregnancy or lactation. 2. Immunotherapy unless at a stable maintenance dose. 3. Presence of a medical condition that might interfere with treatment evaluation or require a change in therapy including but not limited to high blood pressure or urinary retention problems. 4. Alcohol dependence. 5. Use of any other investigational drug in the previous month. 6. Subjects presenting with asthma requiring corticosteroid treatment. 7. Subjects with multiple drug allergies. 8. Subjects known to have an idiosyncratic reaction to any of the ingredients in IMP (STAHIST). 9. Subject who is participating in any other clinical study. 10. Subject who is unable to meet washout requirements. 11. Subject with clinically significant abnormal vital sign or laboratory value that precludes participation. 12. Subject with any family relationship to the sponsor, investigator, or staff of sponsor or investigator. 13. A URI within 4 weeks of study inception. 14. Subjects taking beta blockers or try-cyclic antidepressants. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Symptom Scores(TSS)reported and compared between the two study arms | Twice daily over the 2 week study period | TSS includes the sum of nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events--report and assess | Continuous over the two week study period | Any/all adverse events will be recorded and scored, reported, evaluated, and results will be clinically and statistically compared between the placebo and active drug arms. |
Countries
United States
Outcome results
None listed